Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings
Samo za registrovane korisnike
2020
Autori
Kovačević, TijanaVezmar-Kovačević, Sandra
Stanetić, Mirko
Kovačević, Peđa
Miljković, Branislava
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Background: This study aimed to demonstrate that having clinical pharmacist as a member of oncology team in low and middle income countries might lead to significant reduction in the number of erlotinib interactions in the treatment of non-small cell lung cancer patients. Methods: A group of 44 patients was labeled as intervention group and they were analyzed prospectively in the period from 1 January 2017 to 1 May 2018 during clinical pharmacist’s participation in regular weekly multidisciplinary oncology team meetings. The control group consisted of 44 out of 110 patients treated with erlotinib before the involvement of a clinical pharmacist in oncology team, match paired with 44 patients in intervention group. Results: Clinically significant interactions were identified in two-thirds of studied patients (57 out of 88). Most drug interactions, 38%, potentially result in decrease of serum concentration of erlotinib. Clinical pharmacist provided therapy modification suggestions for 32 ...out of 44 (72.72%) patients in the intervention group, most of which were accepted by doctors. In the intervention group, there were significantly less clinically significant interactions compared to the control group (10 versus 24, p = 0.002). Progression-free survival was significantly longer in the pharmacist’s intervention group (p = 0.001). Conclusions: Clinical pharmacist’s intervention led to significant decrease in erlotinib interactions which may result in treatment optimization of lung cancer patients
Ključne reči:
clinical pharmacist / interaction / lung cancer / Tyrosine kinase inhibitorIzvor:
Journal of Oncology Pharmacy Practice, 2020Izdavač:
- SAGE Publications Ltd
DOI: 10.1177/1078155220921545
ISSN: 1078-1552
WoS: 000532943500001
Scopus: 2-s2.0-85084807144
Institucija/grupa
PharmacyTY - JOUR AU - Kovačević, Tijana AU - Vezmar-Kovačević, Sandra AU - Stanetić, Mirko AU - Kovačević, Peđa AU - Miljković, Branislava PY - 2020 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3594 AB - Background: This study aimed to demonstrate that having clinical pharmacist as a member of oncology team in low and middle income countries might lead to significant reduction in the number of erlotinib interactions in the treatment of non-small cell lung cancer patients. Methods: A group of 44 patients was labeled as intervention group and they were analyzed prospectively in the period from 1 January 2017 to 1 May 2018 during clinical pharmacist’s participation in regular weekly multidisciplinary oncology team meetings. The control group consisted of 44 out of 110 patients treated with erlotinib before the involvement of a clinical pharmacist in oncology team, match paired with 44 patients in intervention group. Results: Clinically significant interactions were identified in two-thirds of studied patients (57 out of 88). Most drug interactions, 38%, potentially result in decrease of serum concentration of erlotinib. Clinical pharmacist provided therapy modification suggestions for 32 out of 44 (72.72%) patients in the intervention group, most of which were accepted by doctors. In the intervention group, there were significantly less clinically significant interactions compared to the control group (10 versus 24, p = 0.002). Progression-free survival was significantly longer in the pharmacist’s intervention group (p = 0.001). Conclusions: Clinical pharmacist’s intervention led to significant decrease in erlotinib interactions which may result in treatment optimization of lung cancer patients PB - SAGE Publications Ltd T2 - Journal of Oncology Pharmacy Practice T1 - Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings DO - 10.1177/1078155220921545 ER -
@article{ author = "Kovačević, Tijana and Vezmar-Kovačević, Sandra and Stanetić, Mirko and Kovačević, Peđa and Miljković, Branislava", year = "2020", abstract = "Background: This study aimed to demonstrate that having clinical pharmacist as a member of oncology team in low and middle income countries might lead to significant reduction in the number of erlotinib interactions in the treatment of non-small cell lung cancer patients. Methods: A group of 44 patients was labeled as intervention group and they were analyzed prospectively in the period from 1 January 2017 to 1 May 2018 during clinical pharmacist’s participation in regular weekly multidisciplinary oncology team meetings. The control group consisted of 44 out of 110 patients treated with erlotinib before the involvement of a clinical pharmacist in oncology team, match paired with 44 patients in intervention group. Results: Clinically significant interactions were identified in two-thirds of studied patients (57 out of 88). Most drug interactions, 38%, potentially result in decrease of serum concentration of erlotinib. Clinical pharmacist provided therapy modification suggestions for 32 out of 44 (72.72%) patients in the intervention group, most of which were accepted by doctors. In the intervention group, there were significantly less clinically significant interactions compared to the control group (10 versus 24, p = 0.002). Progression-free survival was significantly longer in the pharmacist’s intervention group (p = 0.001). Conclusions: Clinical pharmacist’s intervention led to significant decrease in erlotinib interactions which may result in treatment optimization of lung cancer patients", publisher = "SAGE Publications Ltd", journal = "Journal of Oncology Pharmacy Practice", title = "Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings", doi = "10.1177/1078155220921545" }
Kovačević, T., Vezmar-Kovačević, S., Stanetić, M., Kovačević, P.,& Miljković, B.. (2020). Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings. in Journal of Oncology Pharmacy Practice SAGE Publications Ltd.. https://doi.org/10.1177/1078155220921545
Kovačević T, Vezmar-Kovačević S, Stanetić M, Kovačević P, Miljković B. Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings. in Journal of Oncology Pharmacy Practice. 2020;. doi:10.1177/1078155220921545 .
Kovačević, Tijana, Vezmar-Kovačević, Sandra, Stanetić, Mirko, Kovačević, Peđa, Miljković, Branislava, "Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings" in Journal of Oncology Pharmacy Practice (2020), https://doi.org/10.1177/1078155220921545 . .